Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real‐World Study
Cancer Medicine · 2026-11 · 15 (11)
DOI: 10.1002/cam4.72409 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 01.11.2026. Verfasst von Dominika Écsiová und 6 weiteren Autor:innen. Beteiligte Einrichtung: 4th Department of Internal Medicine - Hematology, University Hospital Hradec Králové, Hradec Králové, Czech Republic. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Univerzita Karlova v Praze, Ministerstvo Zdravotnictví Ceské Republiky.
Abstract (Originalsprache)
Background
Obinutuzumab‐based regimens are established frontline treatments for chronic lymphocytic leukemia (CLL), but infusion‐related reactions (IRRs) and prolonged administration increase patient burden and outpatient chair occupancy. Evidence on shortened obinutuzumab infusion in CLL remains limited.
Aims
To evaluate the safety, feasibility, and clinical outcomes of a 2‐h obinutuzumab infusion protocol in treatment‐naïve CLL.
Methods
This retrospective single‐center cohort study included 112 treatment‐naïve patients receiving venetoclax–obinutuzumab ( n = 72) or obinutuzumab–chlorambucil ( n = 40). From cycle 1 day 8 onward, patients were managed according to either a shortened‐infusion strategy (Short; n = 64) or a standard‐duration strategy (Long; n = 48). The primary outcome was IRR incidence and severity; secondary outcomes included chair time, response rate, and progression‐free survival.
Results
IRR rates did not differ significantly between the Short and Long groups (71.9% vs. 83.3%; odds ratio, 0.51; 95% confidence interval, 0.17–1.41; p = 0.18). Most IRRs occurred during the first infusion (87.4%), before implementation of the shortened protocol. Because cycle 1 day 1 and day 2 were administered using the same standard protocol in both groups, the safety comparison relevant to the shortened‐infusion strategy begins at cycle 1 day 8; IRRs were infrequent from cycle 1 day 8 onward, and none occurred from cycle 1 day 15 onward, when eligible patients in the Short group were receiving the 2‐h infusion. Grade 2 reactions predominated (91.6%); no Grade 4 IRRs occurred among the 112 patients included in the analysis. The shortened protocol saved 1.8 h per visit and 11.2 h per patient (42%). No apparent adverse signal in response or progression‐free survival was observed.
Conclusions
In frontline CLL care, a 2‐h obinutuzumab infusion from cycle 1 day 8 was feasible, safe, and substantially reduced chair time, supporting its use to improve outpatient treatment efficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 4th Department of Internal Medicine - Hematology, University Hospital Hradec Králové, Hradec Králové, Czech Republic.
- Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic.
- Tissue Bank, University Hospital Hradec Králové, Hradec Králové, Czech Republic.
- Department of Clinical Pharmacy, Hospital Pharmacy, University Hospital Hradec Králové, Hradec Králové, Czech Republic.
ORCID-Profile: Dominika Écsiová, Eva Vejražková, Pavel Vodárek, Petra Rozsívalová, Lukáš Smolej, Pavel Žák, Martin Šimkovič
Förderung
- Univerzita Karlova v Praze
- Ministerstvo Zdravotnictví Ceské Republiky
Zitieren
APA
Écsiová, D., Vejražková, E., Vodárek, P., Rozsívalová, P., Smolej, L., Žák, P., & Šimkovič, M. (2026). Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real‐World Study. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72409
Vancouver
Écsiová D, Vejražková E, Vodárek P, Rozsívalová P, Smolej L, Žák P, et al. Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real‐World Study. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72409
BibTeX
@article{csiov2026,
author = {Écsiová, Dominika and Vejražková, Eva and Vodárek, Pavel and Rozsívalová, Petra and Smolej, Lukáš and Žák, Pavel and Šimkovič, Martin},
title = {Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real‐World Study},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cam4.72409}
}
EUVIMED